298 related articles for article (PubMed ID: 29110751)
1. Actinobacillus pleuropneumoniae biofilms: Role in pathogenicity and potential impact for vaccination development.
Hathroubi S; Loera-Muro A; Guerrero-Barrera AL; Tremblay YDN; Jacques M
Anim Health Res Rev; 2018 Jun; 19(1):17-30. PubMed ID: 29110751
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial resistance, biofilm formation and virulence reveal Actinobacillus pleuropneumoniae strains' pathogenicity complexity.
Pereira MF; Rossi CC; Seide LE; Martins Filho S; Dolinski CM; Bazzolli DMS
Res Vet Sci; 2018 Jun; 118():498-501. PubMed ID: 29758533
[TBL] [Abstract][Full Text] [Related]
3. Actinobacillus pleuropneumoniae vaccines: from bacterins to new insights into vaccination strategies.
Ramjeet M; Deslandes V; Gouré J; Jacques M
Anim Health Res Rev; 2008 Jun; 9(1):25-45. PubMed ID: 18346296
[TBL] [Abstract][Full Text] [Related]
4. Actinobacillus pleuropneumoniae grows as aggregates in the lung of pigs: is it time to refine our in vitro biofilm assays?
Tremblay YDN; Labrie J; Chénier S; Jacques M
Microb Biotechnol; 2017 Jul; 10(4):756-760. PubMed ID: 27790837
[TBL] [Abstract][Full Text] [Related]
5. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs.
Shin MK; Kang ML; Jung MH; Cha SB; Lee WJ; Kim JM; Kim DH; Yoo HS
Vet Immunol Immunopathol; 2013 Jan; 151(1-2):132-9. PubMed ID: 23206402
[TBL] [Abstract][Full Text] [Related]
6. In vivo testing of novel vaccine prototypes against Actinobacillus pleuropneumoniae.
Antenucci F; Fougeroux C; Deeney A; Ørskov C; Rycroft A; Holst PJ; Bojesen AM
Vet Res; 2018 Jan; 49(1):4. PubMed ID: 29316978
[TBL] [Abstract][Full Text] [Related]
7. Biofilm formation is prevalent among field isolates of Actinobacillus pleuropneumoniae.
Kaplan JB; Mulks MH
Vet Microbiol; 2005 Jun; 108(1-2):89-94. PubMed ID: 15917136
[TBL] [Abstract][Full Text] [Related]
8. Auxotrophic Actinobacillus pleurpneumoniae grows in multispecies biofilms without the need for nicotinamide-adenine dinucleotide (NAD) supplementation.
Loera-Muro A; Jacques M; Avelar-González FJ; Labrie J; Tremblay YD; Oropeza-Navarro R; Guerrero-Barrera AL
BMC Microbiol; 2016 Jun; 16(1):128. PubMed ID: 27349384
[TBL] [Abstract][Full Text] [Related]
9. Method to grow Actinobacillus pleuropneumoniae biofilm on a biotic surface.
Tremblay YD; Lévesque C; Segers RP; Jacques M
BMC Vet Res; 2013 Oct; 9():213. PubMed ID: 24139070
[TBL] [Abstract][Full Text] [Related]
10. New trends in innovative vaccine development against Actinobacillus pleuropneumoniae.
Loera-Muro A; Angulo C
Vet Microbiol; 2018 Apr; 217():66-75. PubMed ID: 29615259
[TBL] [Abstract][Full Text] [Related]
11. Actinobacillus pleuropneumoniae: The molecular determinants of virulence and pathogenesis.
Nahar N; Turni C; Tram G; Blackall PJ; Atack JM
Adv Microb Physiol; 2021; 78():179-216. PubMed ID: 34147185
[TBL] [Abstract][Full Text] [Related]
12. Comparison of metabolic adaptation and biofilm formation of Actinobacillus pleuropneumoniae field isolates from the upper and lower respiratory tract of swine with respiratory disease.
Aper D; Frömbling J; Bağcıoğlu M; Ehling-Schulz M; Hennig-Pauka I
Vet Microbiol; 2020 Jan; 240():108532. PubMed ID: 31902502
[TBL] [Abstract][Full Text] [Related]
13. Attenuated Actinobacillus pleuropneumoniae double-deletion mutant S-8∆clpP/apxIIC confers protection against homologous or heterologous strain challenge.
Xie F; Li G; Zhou L; Zhang Y; Cui N; Liu S; Wang C
BMC Vet Res; 2017 Jan; 13(1):14. PubMed ID: 28061786
[TBL] [Abstract][Full Text] [Related]
14. [Construction and characterization of Actinobacillus pleuropneumoniae serovar 7 live attenuated vaccine strain co-expressing ApxIA].
Liu J; Chen Y; Hu L; Bei W; Chen H
Sheng Wu Gong Cheng Xue Bao; 2010 Mar; 26(3):305-10. PubMed ID: 20518341
[TBL] [Abstract][Full Text] [Related]
15. The Adh adhesin domain is required for trimeric autotransporter Apa1-mediated Actinobacillus pleuropneumoniae adhesion, autoaggregation, biofilm formation and pathogenicity.
Wang L; Qin W; Yang S; Zhai R; Zhou L; Sun C; Pan F; Ji Q; Wang Y; Gu J; Feng X; Du C; Han W; Langford PR; Lei L
Vet Microbiol; 2015 May; 177(1-2):175-83. PubMed ID: 25818350
[TBL] [Abstract][Full Text] [Related]
16. An isogenic Actinobacillus pleuropneumoniae AasP mutant exhibits altered biofilm formation but retains virulence.
Tegetmeyer HE; Fricke K; Baltes N
Vet Microbiol; 2009 Jun; 137(3-4):392-6. PubMed ID: 19217220
[TBL] [Abstract][Full Text] [Related]
17. Nasal immunization with M cell-targeting ligand-conjugated ApxIIA toxin fragment induces protective immunity against Actinobacillus pleuropneumoniae infection in a murine model.
Park J; Seo KW; Kim SH; Lee HY; Kim B; Lim CW; Kim JH; Yoo HS; Jang YS
Vet Microbiol; 2015 May; 177(1-2):142-53. PubMed ID: 25818577
[TBL] [Abstract][Full Text] [Related]
18. Virulence factors of the swine pathogen Actinobacillus pleuropneumoniae.
Tascón RI; Vázquez-Boland JA; Gutiérrez-Martín CB; Rodríguez-Barbosa JI; Rodríguez-Ferri EF
Microbiologia; 1996 Jun; 12(2):171-84. PubMed ID: 8767702
[TBL] [Abstract][Full Text] [Related]
19. Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
Maas A; Meens J; Baltes N; Hennig-Pauka I; Gerlach GF
Vaccine; 2006 Nov; 24(49-50):7226-37. PubMed ID: 17027123
[TBL] [Abstract][Full Text] [Related]
20. Construction of an Actinobacillus pleuropneumoniae serotype 2 prototype live negative-marker vaccine.
Tonpitak W; Baltes N; Hennig-Pauka I; Gerlach GF
Infect Immun; 2002 Dec; 70(12):7120-5. PubMed ID: 12438394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
